Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Swiss pharma giant Roche won approval from the ...

Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.

A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past ...

The CD20-directed cytolytic antibody therapy was approved based on data from two phase 3 trials. Briumvi ™ (ublituximab-xiiy) is now available for the treatment of relapsing forms of multiple ...

Credit: Getty Images. The SC formulation is intended to be administered in 10 minutes twice a year. Positive data were announced from a phase 3 trial evaluating an investigational subcutaneous (SC) ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Briumvi (ublituximab-xiiy) and Ocrevus (ocrelizumab) are prescription drugs used to treat certain types of multiple sclerosis (MS). Both drugs are given as an intravenous (IV) infusion by a healthcare ...

Briumvi (ublituximab-xiiy) is a prescription drug that’s used to treat certain types of multiple sclerosis (MS) in adults. Briumvi is given as an intravenous (IV) infusion by a doctor or other ...

BILLINGS - Staff from St. Vincent Healthcare met at their Regional Neuroscience Center for the grand opening of their brand new state-of-the-art Multiple Sclerosis Infusion Center. Doctors, patients ...

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...